Palantir Technologies is scheduled to release its second-quarter results after the bell tonight, with the shares trading at $125.86 and showing a modest intraday gain. The stock remains down 30.6% year-to-date from its 52-week high of $207.52, yet it continues to carry a very high trailing price-to-earnings multiple in excess of 130x, leaving limited room for missteps.
Wall Street consensus for the quarter stands at $1.81 billion in revenue, which would represent roughly +81% year-over-year growth, and an earnings-per-share consensus of $0.34. Options traders are pricing an expected move of about plus or minus 9.6% around the print.
Market snapshot:
- Last trade: $125.86 (+2.28% today)
- 52-week range: $106.37 to $207.52
- Market capitalization: $300.79 billion
- Options-implied move: ±9.6%
- Consensus EPS: $0.34
- Consensus revenue: $1.81 billion
Investors are weighing two competing narratives heading into the report. Supporters point to an established record of beating expectations and accelerating commercial adoption, while skeptics highlight a stretched valuation, persistent insider sales and signs of competitive pressure in parts of the commercial channel.
The bull argument
Palantir has delivered seven consecutive quarterly EPS beats, with an average surprise north of 16%. The most recent quarter saw a roughly 17.86% beat on both EPS and revenue. That consistency underpins the bullish view that the company can continue to outperform consensus.
Analysts at Oppenheimer are projecting more than 85% year-over-year revenue growth in Q2, citing stronger Department of Homeland Security spending and increased defense demand tied to the Middle East. A partnership announced the morning of the report with Mercury Systems, aimed at automating U.S. military factory operations using Palantir Foundry, is cited by bulls as fresh evidence of a widening government opportunity.
The U.S. commercial business is a central pillar of the upside case. In Q1 2026, U.S. commercial revenue rose 121% year-over-year. Oppenheimer estimates that acceleration continued into Q2, putting U.S. commercial growth above 135% year-over-year. Bulls argue that Palantir AIP adoption remains in early innings with only about 2.4% total market penetration, leaving substantial runway.
Critically for optimists, a guidance increase would be the primary catalyst. Current full-year 2026 guidance sits at $7.18 billion to $7.20 billion; proponents expect management to lift that outlook to reflect greater than 75% growth. Several firms have shown conviction ahead of the print: Citi identified Palantir as a top software pick and D.A. Davidson upgraded the shares to Buy, pointing to improving profitability that, in their view, makes the valuation more palatable.
Proponents also argue a valuation reset has already occurred given the stock's drop from $207 to $125, improving the risk-reward picture for buyers willing to look through near-term volatility.
The bear argument
Even with prior beats, the stock has sometimes moved lower after results. The last two positive surprises were followed by negative price reactions, with the share price falling about 5.66% after Q1 2026 and about 4.85% after Q3 2025. That sequence feeds the concern that the market now expects not just a beat but a beat plus higher guidance as the minimum requirement for meaningful upside.
Commercial partner metrics offer warning signs. Cleveland Research reported that Q2 commercial partner data came in at or below plan, citing increased competition as a contributing factor. That dynamic, if sustained, would directly challenge the thesis that commercial growth will accelerate without margin impact.
Insider selling has also been notable. The company's chief technology officer, Sankar Shyam, sold $24.05 million of shares on July 2, and director Alexander Moore sold $2.14 million on July 15, both under prearranged 10b5-1 plans. While the sales were structured under such plans, the pattern is receiving attention from investors.
Valuation remains a point of contention. Even after the pullback to $125, the shares trade at an implied 50 to 90 times forward revenue in various analyst models. Jefferies continues to carry an Underperform rating with a $70 target, which implies roughly 44% downside from current levels based on the argument that maintaining such a multiple requires near-perfect execution.
International regulatory issues add another layer of uncertainty. A £50 million Metropolitan Police contract was blocked, and parliamentary scrutiny around a £330 million National Health Service agreement in the U.K. creates potential headwinds for global expansion plans.
Key setup metrics
| Bull trigger | Bear trigger |
|---|---|
| Revenue > $1.85B (beat plus raise) | Revenue < $1.81B or in-line only |
| U.S. commercial > 130% YoY confirmed | Signs of commercial deceleration |
| FY guidance raised to > $7.5B | Guidance maintained or lowered |
| Price reaction: reclaim $135+ | Price reaction: move back toward $106 low |
The options market implies about a 9.6% swing on the print, which equates to roughly $112 on the downside or $138 on the upside from the current price. Given the two recent instances where a beat was followed by a selloff, the market appears to be placing the burden of proof on guidance improvements rather than on the beat itself.
Bottom line
Tonight's report will be judged on more than headline beats. Investors will scrutinize U.S. commercial growth, the tone and range of guidance, and any incremental signs of competitive pressure or regulatory friction. With the shares carrying a high multiple even after a major pullback, the margin for disappointment is slim.